Loading clinical trials...
Loading clinical trials...
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
EMD Serono
NCT07536022 · Parkinson's Disease
NCT07594977 · Chronic Cholecystitis, Biliary Dyskinesia
NCT07644013 · Multiple System Atrophy, Parkinson's Disease, and more
NCT07398157 · PD - Parkinson's Disease
NCT07441915 · Parkinson's Disease, Mild Cognitive Impairment
Phoenix, Arizona
Phoenix, Arizona
Phoenix, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions